Literature DB >> 26243742

Evaluation of four human cell lines with distinct biotransformation properties for genotoxic screening.

Laure Khoury1, Daniel Zalko1, Marc Audebert2.   

Abstract

In a previous study, we validated an in vitro genotoxicity assay based on γH2AX quantification using the In-Cell Western (ICW) method in HepG2 cells. The assay demonstrated high sensitivity and specificity but failed to detect genotoxicity for few compounds that require specific metabolic bioactivation not sufficiently covered by HepG2 cells. The aim of the present study was to assess γH2AX ICW sensitivity using a broader range of genotoxic molecules with HepG2 cells and three additional human cell lines with distinct biotransformation properties: two cell lines expressing some phase I and II bioactivation capabilities (LS-174T and Hep3B), and one with poor general bioactivation properties (ACHN). We evaluated the four cell lines by testing 24 compounds recommended by European Centre for the Validation of Alternative Methods and a set of 24 additional chemicals with different mode of genotoxic action (MOA) (aneugenicity, DNA adducts formation, induction of oxidative stress), including some known to require specific cytochrome P450 metabolic bioactivation. Results for the 48 compounds tested showed that the γH2AX ICW assay was more sensitive with LS-174T and HepG2 cells than with Hep3B or ACHN cell lines. Among the 38 compounds tested with positive or equivocal carcinogenicity data, 36 (95%) showed a positive genotoxic response with the γH2AX ICW assay compared to only 27 (71%) using the Ames assay. We confirm that the γH2AX ICW assay on HepG2 cells, without an exogenous metabolic activation system, may be a suitable test to predict the in vivo genotoxicity of chemicals with different genotoxic MOA. Moreover, the use of the ACHN cell line in combination with LS-174T and HepG2 cells may permit in many cases to discriminate direct from bioactivated genotoxins. Overall, our results confirm the high sensitivity of the γH2AX ICW assay which, in turn, should reduce the number of animals used for genotoxicity assessment.
© The Author 2015. Published by Oxford University Press on behalf of the UK Environmental Mutagen Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26243742     DOI: 10.1093/mutage/gev058

Source DB:  PubMed          Journal:  Mutagenesis        ISSN: 0267-8357            Impact factor:   3.000


  4 in total

1.  Performance of high-throughput CometChip assay using primary human hepatocytes: a comparison of DNA damage responses with in vitro human hepatoma cell lines.

Authors:  Ji-Eun Seo; Qiangen Wu; Matthew Bryant; Lijun Ren; Qiang Shi; Timothy W Robison; Nan Mei; Mugimane G Manjanatha; Xiaoqing Guo
Journal:  Arch Toxicol       Date:  2020-04-22       Impact factor: 5.153

2.  Novel insights into the molecular mechanisms underlying risk of colorectal cancer from smoking and red/processed meat carcinogens by modeling exposure in normal colon organoids.

Authors:  Matthew Devall; Christopher H Dampier; Stephen Eaton; Mourad W Ali; Virginia Díez-Obrero; Ferran Moratalla-Navarro; Jennifer Bryant; Lucas T Jennelle; Victor Moreno; Steven M Powell; Ulrike Peters; Graham Casey
Journal:  Oncotarget       Date:  2021-09-14

3.  In Vitro Cell Density Determines the Sensitivity of Hepatocarcinoma Cells to Ascorbate.

Authors:  Hsiu-Lung Fan; Shu-Ting Liu; Yung-Lung Chang; Yi-Lin Chiu; Shih-Ming Huang; Teng-Wei Chen
Journal:  Front Oncol       Date:  2022-05-23       Impact factor: 5.738

4.  Transforming early pharmaceutical assessment of genotoxicity: applying statistical learning to a high throughput, multi end point in vitro micronucleus assay.

Authors:  Amy Wilson; Piotr Grabowski; Joanne Elloway; Stephanie Ling; Jonathan Stott; Ann Doherty
Journal:  Sci Rep       Date:  2021-01-28       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.